García-Jiménez et al. (2025)
- Authors: Álvaro F. García-Jiménez, Arianna Picozzi, Andrea Sánchez de la Cruz, Enrique Vázquez, Alberto Benguría, Ana Dopazo, Vassilios Lougaris, Luis Ignacio González-Granado, Hugh T. Reyburn
- Institutes: Department of Immunology and Oncology, National Centre for Biotechnology, Spanish National Research Council (CNB-CSIC), Madrid, Spain, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, Immunodeficiency Unit, Hospital Universitario 12 de Octubre, Madrid, Spain
- Publisher: Research Square
- Link: DOI
Summary
This study provides the first unbiased, single-cell map of the human immune response that maintains long-term control over the Epstein-Barr virus (EBV). By identifying the specific roles of cytotoxic cells and regulatory T-cells, and discovering the unique virus-killing ability of Vδ1 T-cells, the research offers a new template for understanding why some individuals develop EBV-related diseases or chronic conditions like ME/CFS. This ‘immune blueprint’ may lead to targeted therapies for patients who cannot effectively clear or suppress the virus.
What was researched?
The researchers developed a novel protocol to identify and analyze all immune cells that respond to the Epstein-Barr virus (EBV) in healthy individuals and patients with genetic immune deficiencies.
Why was it researched?
While EBV is nearly universal and linked to many autoimmune and inflammatory diseases, there has been a lack of high-resolution data on how the immune system successfully suppresses the virus over a lifetime.
How was it researched?
The team used single-cell RNA sequencing and a new activation-based detection method to analyze the transcriptome of EBV-responsive lymphocytes from healthy seropositive donors and patients with inborn errors of immunity.
What has been found?
The study found that effective EBV control requires a balance between cytotoxic lymphocytes and regulatory T-cells. It also discovered that a specific population of Vδ1 γδ T cells uses natural killer cell receptors to destroy EBV-infected cells, identifying them as a potential source for allogeneic cell therapy 💊.
Discussion
The research highlights that in patients with immune defects, lymphocytes can still recognize EBV but lack the specific machinery to kill infected cells. This discovery suggest that the Vδ1 T-cell mechanism acts as a key ‘reserve’ defense system that could be harnessed medically.
Conclusion & Future Work
This global map of EBV immunity clarifies the cellular requirements for virus suppression and identifies Vδ1 T-cells as promising candidates for treating EBV-associated complications. Future research is suggested to explore how these specific mechanisms might be impaired in complex chronic illnesses like ME/CFS.